Effect of electroconvulsive therapy on 5-HT1A receptor binding in patients with depression: a PET study with [11C]WAY 100635

Saijo, Tomoyuki; Takano, Akihiro; Suhara, Tetsuya; Arakawa, Ryosuke; Okumura, Masaki; Ichimiya, Tetsuya; Ito, Hiroshi; Okubo, Yoshiro

doi:10.1017/s1461145709991209

Cited by 49 publications

(33 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…75 Applying a region of interest analysis approach, they found no effect of ECT on 5-HT 1A receptor binding in a group of nine patients. Although Saijo et al administered a series of 6–7 bilateral ECTs, we started with unilateral ECT and switched to bilateral ECT in 8 of 12 patients due to insufficient treatment response.…”

Section: Discussionmentioning

confidence: 97%

Global decrease of serotonin-1A receptor binding after electroconvulsive therapy in major depression measured by PET

et al. 2012

View full text Add to dashboard Cite

Electroconvulsive therapy (ECT) is a potent therapy in severe treatment-refractory depression. Although commonly applied in psychiatric clinical routine since decades, the exact neurobiological mechanism regarding its efficacy remains unclear. Results from preclinical and clinical studies emphasize a crucial involvement of the serotonin-1A receptor (5-HT1A) in the mode of action of antidepressant treatment. This includes associations between treatment response and changes in 5-HT1A function and density by antidepressants. Further, alterations of the 5-HT1A receptor are consistently reported in depression. To elucidate the effect of ECT on 5-HT1A receptor binding, 12 subjects with severe treatment-resistant major depression underwent three positron emission tomography (PET) measurements using the highly selective radioligand [carbonyl-11C]WAY100635, twice before (test–retest variability) and once after 10.08±2.35 ECT sessions. Ten patients (∼83%) were responders to ECT. The voxel-wise comparison of the 5-HT1A receptor binding (BPND) before and after ECT revealed a widespread reduction in cortical and subcortical regions (P<0.05 corrected), except for the occipital cortex and the cerebellum. Strongest reductions were found in regions consistently reported to be altered in major depression and involved in emotion regulation, such as the subgenual part of the anterior cingulate cortex (−27.5%), the orbitofrontal cortex (−30.1%), the amygdala (−31.8%), the hippocampus (−30.6%) and the insula (−28.9%). No significant change was found in the raphe nuclei. There was no significant difference in receptor binding in any region comparing the first two PET scans conducted before ECT. This PET study proposes a global involvement of the postsynaptic 5-HT1A receptor binding in the effect of ECT.

show abstract

Section: Discussionmentioning

confidence: 97%

Global decrease of serotonin-1A receptor binding after electroconvulsive therapy in major depression measured by PET

et al. 2012

View full text Add to dashboard Cite

show abstract

“…WAY-100635); or (ii) derivatives of the 5-HT 1A agonist, 8-hydroxy-2-(di- n -propylamino)tetralin (8-OH-DPAT) (Kumar and Mann, 2007; Pike et al, 2001). Among these, [ 3 H] or [ 11 C] labeled WAY-100635 has been the most commonly used 5-HT 1A R antagonist ligand (Assem-Hilger et al, 2010; Saijo et al, 2010; Sargent et al, 2010; Stein et al, 2008). WAY-100635 has more than 100-fold selectivity for 5-HT 1A R versus other receptors except for 5-HT 2B , adrenergic α 1A and dopamine D 4 receptors (Chemel et al, 2006).…”

Section: Introductionmentioning

confidence: 99%

Autoradiographic evaluation of [3H]CUMI-101, a novel, selective 5-HT1AR ligand in human and baboon brain

et al. 2013

View full text Add to dashboard Cite

[11C]CUMI-101 is the first selective serotonin receptor (5-HT1AR) partial agonist radiotracer for positron emission tomography (PET) tested in vivo in nonhuman primates and humans. We evaluated specific binding of [3H]CUMI-101 by quantitative autoradiography studies in postmortem baboon and human brain sections using the 5- HT1AR antagonist WAY100635 as a displacer. The regional and laminar distributions of [3H]CUMI-101 binding in baboon and human brain sections matched the known distribution of [3H]8-OH-DPAT and [3H]WAY100635. Prazosin did not measurably displace [3H]CUMI-101 binding in baboon or human brain sections, thereby ruling out [3H]CUMI-101 binding to α1-adrenergic receptors. This study demonstrates that [11C]CUMI-101 is a selective 5-HT1AR ligand for in vivo and in vitro studies in baboon and human brain.

show abstract

“…Similarly in another study by Lanzenberger et al, PET scan showed substantial reduction of 5HT1A receptorbinding potential (BPND) almost across the entire cortex after one ECT, particularly in amygdala and anterior cingu late cortex [58]. However in another study, after several ECT, BPND did not show consistent result with the former study [59].…”

Section: Effect Of Adjunctive Psychotropic Drugs On Ect Outcomementioning

confidence: 57%

Pharmacogenetics in Electroconvulsive Therapy and Adjunctive Medications

et al. 2015

View full text Add to dashboard Cite

Electroconvulsive therapy (ECT) has shown apparent efficacy in treatment of patients with depression and other mental illnesses who do not respond to psychotropic medications or need urgent control of their symptoms. Pharmacogenetics contributes to an individual's sensitivity and response to a variety of drugs. Clinical insights into pharmacogenetics of ECT and adjunctive medications not only improves its safety and efficacy in the indicated patients, but can also lead to the identification of novel treatments in psychiatric disorders through understanding of potential molecular and biological mechanisms involved. In this review, we explore the indications of pharmacogenetics role in safety and efficacy of ECT and present the evidence for its role in patients with psychiatric disorders undergoing ECT.

show abstract

Effect of electroconvulsive therapy on 5-HT1A receptor binding in patients with depression: a PET study with [11C]WAY 100635

Cited by 49 publications

References 24 publications

Global decrease of serotonin-1A receptor binding after electroconvulsive therapy in major depression measured by PET

Global decrease of serotonin-1A receptor binding after electroconvulsive therapy in major depression measured by PET

Autoradiographic evaluation of [3H]CUMI-101, a novel, selective 5-HT1AR ligand in human and baboon brain

Pharmacogenetics in Electroconvulsive Therapy and Adjunctive Medications

Contact Info

Product

Resources

About